– USA, NJ – TYME Technologies, Inc. (Nasdaq: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, today announced the appointment of Christine Baker to its Board of Directors.
“We are delighted to welcome Christine to our Board of Directors. In addition to Christine’s commercial and business development experience, her considerable industry expertise will be instrumental in helping to guide TYME in our quest to eradicate advanced cancers,” said Board Chairman, Doug Michels.
The Company also announced the appointment of the current Lead Independent Director, Doug Michels as the new Chairman of the Board of Directors, succeeding co-founder Steve Hoffman who has stepped down from his role as CSO but will continue as a member of the Board of Directors.
About Christine D. Baker
Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in business development, commercialization, and drug development strategies. She is currently the CBO of Hookipa Pharma, a public, clinical-stage biotechnology company, where she leads Business Development, Alliance Management, Commercial Strategy, Intellectual Property, and Communications. Before this, Ms. Baker provided commercial development consulting services to biotech companies as the principal of CD Baker Consulting and was also CBO of EpicentRX, a privately held clinical-stage biotechnology company. She also held several management positions at Novartis Pharmaceuticals Corporation, including Vice President and Executive Director, Oncology Early Commercial Strategy. Ms. Baker began her career at Schering-Plough, where she advanced through a variety of roles in R&D, Marketing and Sales, Business Development, and General Management.
“I am impressed with TYME’s pipeline and novel approach to finding solutions that make a difference in people’s lives. As a member of the Board of Directors, I look forward to sharing my experience and perspectives with management as we seek to develop our pipeline,” said Ms. Baker.
Ms. Baker holds a degree in Chemistry from Dartmouth College and an MBA from Rutgers University.
About Douglas A. Michels
Mr. Michels, who has served on TYME’s Board of Directors since October 2018, has over 39 years of experience in the healthcare industry. Most recently, he served as President and CEO of OraSure Technologies, Inc. Before OraSure, Mr. Michels spent 19 years with Johnson & Johnson in a range of executive positions, including as President of Ortho-Clinical Diagnostics International and President of Johnson & Johnson Healthcare Systems. He currently serves on the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST). In February 2010, Mr. Michels was appointed to the Presidential Advisory Council on HIV/AIDS by President Barack Obama.
About TYME Technologies, Inc.
TYME is an emerging biotechnology company developing cancer metabolism-based therapies that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death.
The Company is currently focused on developing its novel compound, SM-88, its preclinical pipeline of novel CMBTTM programs, as well as TYME-19 as a potential therapeutic for SARS CoV-2 diseases. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including prostate, sarcomas, and breast, reinforce the potential of its emerging CMBT pipeline.
For more information: https://tymeinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
